SOURCE: Bellwether Report

May 04, 2005 12:36 ET

The Bellwether Report's Prospecting Team Has Dug Up These 4 "Diamonds in the Rough:" BCII, NYNY, ALTI, and NGEN

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.

TORONTO -- (MARKET WIRE) -- May 4, 2005 -- The Bellwether Report is the leading online financial newsletter, focusing on small-cap emerging growth opportunities. We strive to introduce investors to truly undervalued opportunities in a time-friendly fashion, allowing for optimal entry points and profitable exit points.

Bone Care International Inc. (NASDAQ: BCII); Empire Resorts Inc. (NASDAQ: NYNY); Altair Nanotechnologies Inc. (NASDAQ: ALTI); and Nanogen Inc. (NASDAQ: NGEN). Investors interested in any of the above-mentioned companies are invited to sample the Bellwether Report for 30 days complimentary, and receive a full report on the company of your choosing.

Bone Care International Inc. is a specialty pharmaceutical company engaged in the discovery, development and commercialization of therapeutic products to treat the medical needs of patients with debilitating conditions and life-threatening diseases. Stock rose quickly 35% following today's announcement that Genzyme will acquire Bone Care for about $600 million in cash.

Empire Resorts Inc. has served as a holding company for subsidiaries engaged in the ownership, development and operation of gaming facilities. Shares rose 29% following today's announcement that the New York Court of Appeals upheld the position regarding the validity of gaming laws passed by the New York Legislature in 2001.

Altair Nanotechnologies Inc. has developed a technology platform for manufacturing a wide variety of nanomaterials and nano-based products. The company's shares were up 9% this morning following last week's first-quarter financial results conference call.

Finally, Nanogen Inc. is an advanced diagnostic company and generates revenue through contract research, grants, and licenses and also through commercializing molecular diagnostic research tools. Shares soared 20% after reporting a loss of $8.3 million or 17 cents a share, for the first quarter.

For a daily and up-to-date informative service featuring other exciting companies like those listed above, feel free to visit and sign up. Sixteen thousand subscribers have, why don't you? Remember... NO credit card needed!!

The Bellwether Report to date has not been compensated by any of the above-mentioned companies.

Contact Information